The development of benign prostatic hyperplasia (BPH) requires aging and testicular androgens; BPH does not develop in patients castrated prior to puberty. Therefore, androgen withdrawal therapy aimed at alleviating or preventing the progression of BPH is rational. Androgen ablation leads to partial involution of the hyperplastic gland, but improvement in urinary flow rate and symptoms occur in a minority of patients. More selective androgen blockade with the 5-alpha reductase inhibitor, finasteride, achieves a significant decrease in intra-prostatic dihydrotestosterone (DHT) with minimal toxicity, but mean prostate volume reduction is limited to 20%. Significant clinical improvement occurs in only one-third of men treated with 5mg of finasteride daily for one year. To date, the probability of clinical improvement has not correlated with initial prostatic volume, serum prostate specific antigen levels, or other clinical parameters. More detailed knowledge of baseline prostatic physiology and potential heterogeneity is needed than current BPH clinical trials provide.
The specific aims of the current proposal are to: 1) determine if finasteride produces a sustained or progressive decrease in prostate volume, urodynamic obstruction, and symptom score, while increasing uroflow rate compared to placebo, 2) determine what baseline clinical, histologic, or biochemical studies predict treatment response, and 3) determine what baseline clinical, histologic, or biochemical studies predict the natural history of BPH (placebo group). This four year study will randomize patients to placebo or 5mg of finasteride daily. In addition to classic clinical endpoints, prostatic biopsies will be analyzed for stromaepithelial cell ratios, T and DHT concentrations, and 5-alpha reductase isozyme expression, The initial pilot phase will focus on study design and the feasibility of tissue analyzes which require invasive procedures.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01DK046437-01
Application #
3551071
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1992-09-30
Project End
1995-03-31
Budget Start
1992-09-30
Budget End
1993-06-30
Support Year
1
Fiscal Year
1992
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Kaplan, Steven A; Lee, Jeannette Y; O'Neill, Edward A et al. (2013) Prevalence of low testosterone and its relationship to body mass index in older men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Aging Male 16:169-72
Kaplan, Steven A; Lee, Jeannette Y; Meehan, Alan G et al. (2011) Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial. J Urol 185:1369-73
Kaplan, Steven A; Roehrborn, Claus G; McConnell, John D et al. (2008) Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial. J Urol 180:1030-2;discussion 1032-3
Johnson 2nd, Theodore M; Burrows, Pamela K; Kusek, John W et al. (2007) The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia. J Urol 178:2045-50;discussion 2050-1
Crawford, E David; Wilson, Shandra S; McConnell, John D et al. (2006) Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol 175:1422-6; discussion 1426-7
Kaplan, Steven A; McConnell, John D; Roehrborn, Claus G et al. (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175:217-20; discussion 220-1
McConnell, John D; Roehrborn, Claus G; Bautista, Oliver M et al. (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387-98
McConnell, J D (1995) Prostatic growth: new insights into hormonal regulation. Br J Urol 76 Suppl 1:5-10